Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study. (Q52646483)

From Wikidata

Jump to navigation Jump to search

scientific article published on 20 March 2018

Language	Label	Description	Also known as
English	Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study.	scientific article published on 20 March 2018

Statements

scholarly article

1 reference

Europe PubMed Central

5 May 2018

http://europepmc.org/abstract/PMC/5859435

Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study. (English)

1 reference

Europe PubMed Central

5 May 2018

http://europepmc.org/abstract/PMC/5859435

1 reference

based on heuristic

inferred from title

object named as

Jeong-Hoon Lee

3

0 references

author name string

Hwi Young Kim

1

1 reference

Europe PubMed Central

5 May 2018

http://europepmc.org/abstract/PMC/5859435

Dong Hyeon Lee

2

1 reference

Europe PubMed Central

5 May 2018

http://europepmc.org/abstract/PMC/5859435

Young Youn Cho

4

1 reference

Europe PubMed Central

5 May 2018

http://europepmc.org/abstract/PMC/5859435

Eun Ju Cho

5

1 reference

Europe PubMed Central

5 May 2018

http://europepmc.org/abstract/PMC/5859435

Su Jong Yu

6

1 reference

Europe PubMed Central

5 May 2018

http://europepmc.org/abstract/PMC/5859435

Yoon Jun Kim

7

1 reference

Europe PubMed Central

5 May 2018

http://europepmc.org/abstract/PMC/5859435

Jung-Hwan Yoon

8

1 reference

Europe PubMed Central

5 May 2018

http://europepmc.org/abstract/PMC/5859435

language of work or name

0 references

publication date

20 March 2018

1 reference

Europe PubMed Central

5 May 2018

http://europepmc.org/abstract/PMC/5859435

1 reference

Europe PubMed Central

5 May 2018

http://europepmc.org/abstract/PMC/5859435

18

1 reference

Europe PubMed Central

5 May 2018

http://europepmc.org/abstract/PMC/5859435

307

1 reference

Europe PubMed Central

5 May 2018

http://europepmc.org/abstract/PMC/5859435

1

1 reference

Europe PubMed Central

5 May 2018

http://europepmc.org/abstract/PMC/5859435

copyright license

Creative Commons Attribution 4.0 International

20 March 2018

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

https://scigraph.springernature.com/pub.10.1186/s12885-018-4211-2

0 references

Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

22 May 2018

Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

22 May 2018

Liver cancer: Approaching a personalized care

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

22 May 2018

Reproducible complete remission of advanced hepatocellular carcinoma with sorafenib in combination with clopidogrel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

22 May 2018

Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

22 May 2018

Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

22 May 2018

Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

22 May 2018

Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

22 May 2018

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

22 May 2018

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

22 May 2018

Tivantinib in hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

22 May 2018

Trastuzumab emtansine for HER2-positive advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

22 May 2018

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

22 May 2018

Cancer biomarkers: selecting the right drug for the right patient

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

22 May 2018

Tumor-platelet interaction in solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

22 May 2018

Protein induced by vitamin K absence or antagonist-II production is a strong predictive marker for extrahepatic metastases in early hepatocellular carcinoma: a prospective evaluation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

22 May 2018

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

22 May 2018

Management of hepatocellular carcinoma: An update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

22 May 2018

Platelets: linking hemostasis and cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

22 May 2018

The platelet contribution to cancer progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

22 May 2018

Predictive biomarker validation in practice: lessons from real trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

22 May 2018

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

22 May 2018

Use of archived specimens in evaluation of prognostic and predictive biomarkers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

22 May 2018

Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

22 May 2018

Complete blood count reflects the degree of oesophageal varices and liver fibrosis in virus-related chronic liver disease patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

22 May 2018

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

22 May 2018

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

22 May 2018

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

22 May 2018

Design and endpoints of clinical trials in hepatocellular carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

22 May 2018

The cancer biomarker problem

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

22 May 2018

Validation of pharmacogenomic biomarker classifiers for treatment selection.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

22 May 2018

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

22 May 2018

Biomarkers in cancer staging, prognosis and treatment selection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

22 May 2018

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

22 May 2018

Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

22 May 2018

Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

13 August 2018

Reporting recommendations for tumor marker prognostic studies (REMARK).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

13 August 2018

Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

13 August 2018

A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

13 August 2018

Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

13 August 2018

Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5859435

30 November 2018

Implications of serum basic fibroblast growth factor levels in chronic liver diseases and hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/29558905

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Basic fibroblast growth factor regulates proliferation and motility of human hepatoma cells by an autocrine mechanism

1 reference

https://pubmed.ncbi.nlm.nih.gov/29558905

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/29558905

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PIVKA-II is an independent prognostic factor for overall survival of HCC patients and maybe associated with epithelial-mesenchymal transition

1 reference

https://pubmed.ncbi.nlm.nih.gov/29558905

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/S12885-018-4211-2

1 reference

Europe PubMed Central

5 May 2018

http://europepmc.org/abstract/PMC/5859435

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

5 May 2018

http://europepmc.org/abstract/PMC/5859435

1 reference

Europe PubMed Central

5 May 2018

http://europepmc.org/abstract/PMC/5859435

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52646483&oldid=2129805400"